Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Nevada PERS Names Successor to Manage the $79 Billion Passive Portfolio James Comtois For Members Only After a Remarkable Run, Concentration Cuts Both Ways Stephen Taub Rethinking Equity Allocation From a Global Perspective Sponsored by Capital Group